Trial Profile
XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Pulmonary embolism; Venous thrombosis
- Focus Pharmacodynamics
- Acronyms XENITH
- 08 Jul 2016 Status changed from not yet recruiting to discontinued.
- 24 Jul 2015 New trial record